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Background: Cardiac diseases (e.g. coronary and valve) are associated with ventricular cellular remodeling.
However, ventricular biopsies from left and right ventricles from patients with different pathologies are rare and
thus little is known about disease-induced cellular remodeling in both sides of the heart and between different
diseases. We hypothesized that the protein expression profiles between right and left ventricles of patients with
aortic valve stenosis (AVS) and patients with coronary artery disease (CAD) are different and that the protein profile is
different between the two diseases. Left and right ventricular biopsies were collected from patients with either CAD or
AVS. The biopsies were processed for proteomic analysis using isobaric tandem mass tagging and analyzed by reverse
phase nano-LC-MS/MS. Western blot for selected proteins showed strong correlation with proteomic analysis.
Results: Proteomic analysis between ventricles of the same disease (intra-disease) and between ventricles of different
diseases (inter-disease) identified more than 500 proteins detected in all relevant ventricular biopsies. Comparison
between ventricles and disease state was focused on proteins with relatively high fold (±1.2 fold difference) and
significant (P < 0.05) differences. Intra-disease protein expression differences between left and right ventricles were largely
structural for AVS patients and largely signaling/metabolism for CAD. Proteins commonly associated with hypertrophy
were also different in the AVS group but with lower fold difference. Inter-disease differences between left ventricles of
AVS and CAD were detected in 9 proteins. However, inter-disease differences between the right ventricles of CAD and
AVS patients were associated with differences in 73 proteins. The majority of proteins which had a significant difference in
one ventricle compared to the other pathology also had a similar trend in the adjacent ventricle.
Conclusions: This work demonstrates for the first time that left and right ventricles have a different proteome and that
the difference is dependent on the type of disease. Inter-disease differential expression was more prominent for right
ventricles. The finding that a protein change in one ventricle was often associated with a similar trend in the adjacent
ventricle for a large number of proteins suggests cross-talk proteome remodeling between adjacent ventricles.
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Studies investigating cardiac gene and protein expression
profiling in disease state provide insight into patho-
physiological mechanisms and improve our understand-
ing of cardiac cellular remodeling which can help in the
development of new therapeutic drugs. Although gene
and protein expression profiling have been carried out in* Correspondence: m.s.suleiman@bristol.ac.uk
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article, unless otherwise stated.hearts of experimental models of disease, these models
have significant limitations. For example non-transgenic
models of coronary artery disease involve acute ischemia
rather than progressive atherosclerotic coronary disease
which would trigger cardiac remodeling [1]. In contrast
there are several models of ventricular hypertrophy that
have been extensively used and do provide useful infor-
mation. Ideally, gene and protein profiling studies need
to be carried out using human tissue. However, studies
using human cardiac tissues are rare and have mostly fo-
cused on global gene expression in failing and non-tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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tissue [2-5]. More recently, a comparative study of global
gene expression analysis performed on human paired sam-
ples collected from the right atrial appendage and from
the left ventricle of patients with mixed pathologies (cor-
onary artery bypass graft and aortic valve replacement)
identified 542 genes as differentially expressed which cor-
responded to ∼ 2% of the genes covered by the microarray
[6]. Gene expression profiling may not be sufficient to im-
plicate disease progression as protein levels would be
more informative. For example a study looking at familial
hypertrophic cardiomyopathy caused by a mutation of the
beta-myosin heavy chain could not detect differences in
the expression of myosin mRNA between left and right
ventricles [7]. To the best of our knowledge, there are no
studies looking at protein profiling in left and right ventri-
cles of patients with aortic valve stenosis (AVS) and coron-
ary artery disease (CAD).
In this novel study we hypothesized that cardiac dis-
eases trigger different proteomic remodeling in left and
right ventricles and that the extent of remodeling varies
with disease type. To address this hypothesis we used
proteomic analysis on tissues from the right and left
ventricles of patients with either AVS or CAD.
Results
Comparison between proteomic analysis and western
blotting for catalase
To ensure that our proteomic analysis has some validity,
we carried out western blotting using the same samples
for standard proteins that have available antibodies and
are widely used. Catalase and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) expression measured using
western blotting showed similar variation to those ob-
tained using proteomic analysis. Samples from both AVS
and CAD patients and from both left and right ventricles
were selected for western blot analysis. The western blot
for catalase and GAPDH and ratios of intensity for the se-
lected samples are shown in Figure 1A. The results com-
pared favorably with the proteomic analysis for catalase
and GAPDH as shown in Figure 1B. In fact there was an
excellent (R2 = 0.90) and significant (P < 0.05) correlation
between the western blot analysis and the proteomic ana-
lysis for the ratio of catalase/GAPDH (Figure 1C). It must
be emphasized however, that this successful validation
may not necessarily apply to other proteins or the overall
proteomics results.
The effect of disease on proteomes of paired samples
from left and right ventricles of the same patients
Aortic valve stenosis
Overall more than 1700 proteins were detected using
this proteomic analysis. However, only 603 proteins were
detected in both the right and left ventricles of all AVSpatients. In 34 (5.6%) of these proteins there was a signifi-
cant difference between the two ventricles (Figure 2A).
However, there were only four proteins with relatively high
fold difference (log2 fold difference > 0.25) in the left com-
pared to right ventricle; lumican, vimentin, filamin-A and
mitogen-activated protein kinase 14 (Figure 2A). All four
proteins were higher in the hypertrophic left ventricle
compared to the right ventricle. In addition, proteins com-
monly associated with hypertrophy were also detected and
were significantly lower in the left ventricle compared to
the right ventricle but had a relatively low fold difference.
These include sarcoplasmic reticulum Ca2+ ATPase (log2
fold difference = −0.129 and P = 0.01) [8,9] and myosin-
binding protein C (log2 fold difference = −0.246 and P =
0.02) [10,11].
Coronary artery disease
There were 591 proteins detected in both the right and
left ventricles of all CAD patients, of which 64 (10.8%)
were significantly different between the two ventricles
(Figure 2B). However, there were only six proteins (1.0%)
with relatively high fold difference (log2 fold diffe-
rence > 0.25) in left compared to right ventricle and they
were all higher in the left ventricle (Figure 2B); cathepsins
B and D, nucleobindin-1, 60 kDa heat shock protein,
glycogen synthase and MAP7 domain-containing protein
1. The volcano plot (Figure 2B) comparing left and right
ventricles showed a shift to the right side indicating that
there are more proteins with higher expression in left ven-
tricle compared to right ventricle.
Proteomic analysis comparing ventricles between
patients with AVS and patients with CAD
Left ventricles
There were 516 proteins detected in all left ventricles of
AVS and CAD patients, of which 13 (2.5%) were signifi-
cantly different between the left ventricle of AVS and the
left ventricle of CAD patients (Figure 3A). However, there
were only three (0.6%) proteins with relatively high fold dif-
ference (log2 fold difference > 0.25) which were higher in
AVS left ventricle compared to CAD left ventricle, which
were: sodium channel protein type 5 subunit alpha, 2-
oxoisovalerate dehydrogenase subunit alpha and glyco-
gen synthase (Additional file 1: Table S1). Additionally,
there were six (1.2%) proteins which were lower with
relatively high fold difference (log2 fold difference > 0.25) in
the left ventricle of AVS compared to left ventricle of CAD
patients: glutathione S-transferase P, myomesin-1 and 2,
proactivator polypeptide, apoptotic chromatin condensa-
tion inducer in the nucleus and heterogeneous nuclear ri-
bonucleoproteins C1/C2 (Additional file 1: Table S1).
In addition to these proteins that had high fold differ-
ence, the proteins that are commonly associated with
hypertrophy also showed a strong fold difference but did
Figure 1 Comparing proteomics and western blot analysis for catalase. A) Western blot membranes and quantification of catalase protein
expression normalized to GAPDH protein expression. B) Proteomics quantification for catalase normalized to GAPDH. The samples used in the
western blot were the same samples that were used in the proteomics analysis. C) A scatter graph to show the correlation between the
quantification of the western blot and the proteomics analysis and a R2 value of 0.90 was achieved demonstrating excellent correlation.
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Figure 2 Protein comparison between the left and right ventricles of each disease. A) Volcano plot of the entire set of proteins quantified
in the left and right ventricles of AVS patients. B) Volcano plot of the entire set of proteins quantified in the left and right ventricles of CAD
patients. Each point represents the difference in expression (log2 fold difference) between left and right ventricles plotted against the level of
statistical significance. Solid lines represent ± 1.2 fold difference and a significance level of P < 0.05 (Student’s t-test). Proteins represented by (x)
had less than ± 1.2 fold difference or were not statistically significant. Proteins represented by a (•) had greater than ± 1.2 fold difference and were
statistically significant.
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mic reticulum Ca2+ ATPase (log2 fold difference = −0.243
and P = 0.07) [8,9] and myosin-binding protein C (log2
fold difference = −0.691 and P = 0.11) [10,11].Right ventricles
Of the 516 proteins detected in all right ventricles of the
AVS and CAD patients there was a significant difference
in 92 (17.8%) of proteins (Figure 3B). In the right ven-
tricle of AVS patients there were 73 (14.1%) proteins
which were significantly altered and had a log2 fold dif-
ference > 0.25 compared to right ventricle of CAD pa-
tients; of these, 65 were higher and 8 lower in AVS
compared to CAD patients. These proteins included 22
that were related to metabolism, 15 that had roles in cell
signaling and 11 that were structural proteins (Additional
file 1: Table S2-S4).Protein expression profiling in left and right ventricles
comparing disease related trends
There were four proteins that were significantly altered
in both the left and right ventricle of the AVS patients
compared to both the left and right ventricles of CAD
patients; glycogen synthase, 2-oxoisovalerate dehydro-
genase subunit alpha, sodium channel protein type 5
subunit alpha and apoptotic chromatin condensation in-
ducer in the nucleus (Table 1). There were 26 proteins
that were significantly altered in both the left and right
ventricle of the AVS group compared to one of the CAD
ventricles (Table 1). Additionally, there were 72 proteins
that were significantly altered in one of the AVS ventri-
cles compared to one of the CAD ventricles and had a
similar trend in the adjacent AVS ventricle. The proteins
that showed this pattern were divided into groups re-
lated to metabolism (Table 2), structural and cell signal-
ing (Table 3) and other (Table 4). The majority (84%) of
Figure 3 Protein comparison between CAD and AVS patients. A) Volcano plot of the entire set of proteins quantified in the left ventricle of
CAD and AVS patients. B) Volcano plot of the entire set of proteins quantified in the right ventricle of CAD and AVS patients. Each point
represents the difference in expression (log2 fold difference) between CAD and AVS patients plotted against the level of statistical significance.
Solid lines represent ± 1.2 fold difference and a significance level of P < 0.05 (Student’s t-test). Proteins represented by (x) had less than ± 1.2 fold
difference or were not statistically significant. Proteins represented by (•) had greater than ± 1.2 fold difference and were statistically significant.
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both ventricles of one disease compared to the other
were higher in the AVS patients.
Discussion
In this novel work we used proteomic analysis involving
tandem mass tagging followed by reverse phase nano-
liquid chromatography mass spectrometry/mass spec-
trometry (LC-MS/MS) to compare protein levels between
different ventricles from two different diseases: AVS and
CAD. Successful strong correlation between proteomic
analysis and western blotting for two proteins suggests this
proteomic method is valid although more studies are
needed before making a firm conclusion.
This work shows for the first time significant intra-
and inter-ventricular differences in protein profiling in-
cluding; i) between left and right ventricles of patients
with AVS and CAD, ii) between the left ventricles of thetwo pathologies, iii) between the right ventricles of the
two pathologies and iv) between ventricular tissues of
AVS compared to CAD, irrespective of the side of the
heart. The pattern of differential abundances for a large
number of proteins tended to be similar for the same
disease but different between the diseases.
The main proteins differentially expressed between left
and right ventricles of the same heart in patients with
AVS are structural
Aortic valve stenosis is associated with left ventricular
hypertrophy. Therefore it is expected that there will be
significant differences in protein profiling between the
hypertrophic left and the relatively normal right ventri-
cles. Surprisingly there were only four proteins that were
differentially expressed (significant and greater than 1.2
fold difference) between left and right ventricles. Three
of these proteins (lumican, vimentin and filamin-A) were
Table 1 Proteins differentially expressed in both AVS ventricles compared to at least one CAD ventricle
Log2 fold diff. vs. RVCAD
Protein [Swiss-Prot accession number] LVCAD RVAVS LVAVS
Both ventricles of AVS vs. both ventricles of CAD
Glycogen [starch] synthase, muscle [P13807] 0.25* 0.85*# 0.72*#
2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial [P12694] 0.08 0.54*# 0.52*#
Sodium channel protein type 5 subunit alpha [Q14524] −0.10 0.43*# 0.65*#
Apoptotic chromatin condensation inducer in the nucleus [Q9UKV3] 0.09 −0.50*# −0.51*#
Both ventricles of AVS vs. one ventricle of CAD
Unconventional myosin-XVIIIb [Q8IUG5] 0.09 0.81*# 0.79*
Nestin [P48681] 0.23 0.60* 0.53*
Thiomorpholine-carboxylate dehydrogenase [Q14894] 0.19 0.52* 0.74*
60 kDa heat shock protein, mitochondrial [P10809] 0.25* 0.48* 0.39*
PDZ and LIM domain protein 5 [Q96HC4] 0.05 0.45* 0.30*
Amine oxidase [flavin-containing] A [P21397] 0.28 0.45* 0.34*
Peptidyl-prolyl cis-trans isomerase F, mitochondrial [P30405] 0.15 0.44* 0.39*
ATP-binding cassette sub-family F member 1 [Q8NE71] 0.06 0.43*# 0.27*
Enoyl-CoA delta isomerase 2, mitochondrial [O75521] 0.18 0.39* 0.32*
Hexokinase-1 [P19367] 0.26 0.39* 0.43*
Protein NipSnap homolog 2 [O75323] 0.08 0.33* 0.29*
Phosphoglycerate mutase 1 [P18669] 0.16* 0.33* 0.33*
GTP:AMP phosphotransferase AK4, mitochondrial [P27144] 0.18 0.32* 0.23*
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial [Q16836] 0.17* 0.31* 0.23*
Aspartate aminotransferase, mitochondrial [P00505] 0.13 0.30* 0.24*
Annexin A11 [P50995] 0.10* 0.30* 0.22*
Glutathione S-transferase kappa 1 [Q9Y2Q3] 0.09 0.28* 0.26*
Elongation factor Tu, mitochondrial [P49411] 0.13* 0.26* 0.22*
Moesin [P26038] 0.03 0.23*# 0.21*
Alpha-2-macroglobulin [P01023] 0.37 −0.77* −0.71*
Alpha-1-acid glycoprotein 1 [P02763] 0.09 −0.80* −0.69*
Haptoglobin [P00738] 0.28 −1.46* −1.41*
Elongation factor 1-alpha 2 [Q05639] −0.07 0.16*# 0.09#
Peroxiredoxin-1 [Q06830] −0.04 −0.17# −0.23#
Proactivator polypeptide [P07602] 0.24* −0.33# −0.34#
Heterogeneous nuclear ribonucleoproteins C1/C2 [P07910] 0.05 −0.60# −0.61#
Proteins significantly altered in both the left and right ventricles of the AVS patients compared to the left and/or right ventricle(s) of CAD patients. Data are
presented as log2 fold difference compared to the right ventricle of the CAD patients.
*P < 0.05 vs. RVCAD and
#P < 0.05 vs. LVCAD.
Fold diff. = Fold difference.
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left ventricle. Lumican is a small extracellular matrix-
localized proteoglycan, produced by cardiac fibroblasts
and plays a role in the fibrillogenesis following insults
[12,13]. Lumican gene expression was differentially
expressed in dilated cardiomyopathy [14] and its precursor
was found at higher abundance in the atrial appendage of
patients with AVS compared to CAD [15]. Similarly,
vimentin is reported to increase in patients with dilatedcardiomyopathy which may reflect activation of interstitial
cells and fibrosis during the transition to heart failure
[16-19]. Elevated filamins play an essential role in the
maintenance of cardiac structural integrity and is altered
in cardiomyopathies including aortic stenosis [20-22]. It is
important to emphasize that these published studies did
not compare left and right ventricular tissue. In addition
to the three structural proteins, the levels of mitogen-
activated protein kinase 14 in the left ventricle was higher
Table 2 Inter-disease trends: metabolism-related proteins
Log2 fold diff. vs. RVCAD
Protein [Swiss-Prot accession number] LVCAD RVAVS LVAVS
Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial [P55809] 0.14 0.63*# 0.37
UTP–glucose-1-phosphate uridylyltransferase [Q16851] 0.03 0.47*# 0.37
ADP/ATP translocase 2 [P05141] 0.11 0.42*# 0.38
Acyl-coenzyme A thioesterase 9, mitochondrial [Q9Y305] −0.05 0.39*# 0.29
Dihydrolipoyl dehydrogenase, mitochondrial [P09622] 0.12 0.37*# 0.28
Cytochrome c [P99999] 0.05 0.31*# 0.24
Phosphoglucomutase-1 [P36871] −0.02 0.15*# 0.07
Acetyl-coenzyme A synthetase, cytoplasmic [Q9NR19] 0.07 −0.20*# −0.17
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial [P11310] 0.09 0.42* 0.34
D-beta-hydroxybutyrate dehydrogenase, mitochondrial [Q02338] 0.20 0.41* 0.34
Enoyl-CoA hydratase, mitochondrial [P30084] 0.15* 0.38* 0.26
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate
dehydrogenase complex, mitochondrial [P10515]
0.12 0.35* 0.29
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate
dehydrogenase complex, mitochondrial [P36957]
0.10 0.34* 0.26
Fumarate hydratase, mitochondrial [P07954] 0.12 0.34* 0.25
Amine oxidase [flavin-containing] B [P27338] 0.06 0.25* 0.13
ADP/ATP translocase 1 [P12235] 0.13 0.24* 0.15
Electron transfer flavoprotein subunit beta [P38117] 0.08* 0.22* 0.14
Fatty acid-binding protein, heart [P05413] 0.03 0.21* 0.18
Malate dehydrogenase, cytoplasmic [P40925] 0.05 0.20* 0.13
Pyruvate dehydrogenase protein X component, mitochondrial [O00330] 0.05 0.34# 0.27
Glycogen phosphorylase, brain form [P11216] −0.01 0.29# 0.23
Phosphatidate cytidylyltransferase 2 [O95674] 0.01 0.26# 0.17
Triosephosphate isomerase [P60174] 0.05 −0.04# −0.03
Proteins (metabolism-related) significantly altered in one of the AVS ventricles compared to either the left or right ventricle of CAD group and had a similar trend
in the adjacent AVS ventricle. Data are presented as log2 fold difference compared to the right ventricle of the CAD patients.
*P < 0.05 vs. RVCAD and
#P < 0.05 vs. LVCAD.
Fold diff. = Fold difference.
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survival pathway in response to pressure overload [23]
and in the pathogenesis of dilated cardiomyopathy [24].
In addition, the patients in the AVS group demonstrated
changes in proteins commonly associated with hypertrophy
(sarcoplasmic reticulum Ca2+ ATPase and myosin-
binding protein C) confirming the presence of hyper-
trophy in the left ventricle of these patients; however, it
is likely the hypertrophy was mild as the fold difference
was relatively low.
The main proteins differentially expressed between left
and right ventricles of the same heart in patients with
CAD are signaling related
Despite the presence of chronic coronary atherosclerotic
disease, areas distal to main occlusion can still receive
sufficient blood flow due to coronary flow reserve and
collateralization. However, the severity of the stenosisand the extent of diffuse CAD will determine resting
coronary flow or reserve in diseased myocardial seg-
ments [25]. Additionally, patients in this study were hav-
ing bypass grafts for vessels supplying the left and right
ventricles in areas distal to the apex where biopsies were
collected. Nonetheless, there were several proteins that
were significantly more expressed and had relatively
high fold difference in the left ventricle compared to
right ventricle. These proteins were cathepsins B and D,
nucleobindin-1, 60 kDa heat shock protein, glycogen
synthase and MAP7 domain-containing protein 1. The
difference in the expression of these proteins can be due
to differences between left and right ventricles and/or
due to severity of disease present.
Cathepsins (cysteine proteases) are implicated in cardio-
vascular disease and their inhibition is cardioprotective in
animal models [26,27] and can degrade unwanted intracel-
lular proteins during ischemic disease [28]. Similarly, the
Table 3 Inter-disease trends: structural and cell signaling-related proteins
Log2 fold diff. vs. RVCAD
Protein [Swiss-Prot accession number] LVCAD RVAVS LVAVS
Structural
Actin, alpha skeletal muscle [P68133] −0.15 0.75*# 0.45
Versican core protein [P13611] 0.06 0.68*# 1.04
Tubulin alpha-4A chain [P68366] 0.17 0.56*# 0.41
Cofilin-2 [Q9Y281] 0.05 0.52*# 0.38
Myopalladin [Q86TC9] 0.02 0.49*# 0.42
Talin-2 [Q9Y4G6] −0.02 −0.42*# −0.37
CLIP-associating protein 1 [Q7Z460] 0.11 0.29* 0.17
Ezrin [P15311] −0.01 0.25* 0.16
Myosin-9 [P35579] 0.02 0.38 0.34*
LIM domain and actin-binding protein 1 [Q9UHB6] 0.14 0.22 0.46*
Myomesin-2 [P54296] 0.10 −0.05 −0.20#
Myomesin-1 [P52179] 0.04 −0.10 −0.24#
Cell Signaling
Inactive dual specificity phosphatase 27 [Q5VZP5] 0.02 0.67*# 0.61
Protein phosphatase 1 regulatory subunit 7 [Q15435] 0.09 0.42*# 0.21
Tight junction protein ZO-1 [Q07157] 0.08 0.40*# 0.35
Heat shock protein beta-1 [P04792] 0.06 0.34*# 0.26
Heat shock cognate 71 kDa protein [P11142] 0.06 0.22*# 0.14
10 kDa heat shock protein, mitochondrial [P61604] 0.24* 0.41* 0.32
Glycogen synthase kinase-3 beta [P49841] 0.05 0.39* 0.32
Apoptosis-inducing factor 1, mitochondrial [O95831] 0.12 0.33* 0.22
Thioredoxin-dependent peroxide reductase, mitochondrial [P30048] 0.12 0.32* 0.22
Calsequestrin-2 [O14958] 0.03 0.31* 0.14
78 kDa glucose-regulated protein [P11021] 0.07 0.29* 0.22
Stress-70 protein, mitochondrial [P38646] 0.13 0.26* 0.21
Heat shock protein beta-7 [Q9UBY9] −0.09 0.69# 0.55
Glutathione S-transferase P [P09211] 0.09 −0.16 −0.19#
Proteins (structural and cell signaling-related) significantly altered in one of the AVS ventricles compared to either the left or right ventricle of CAD group and had
a similar trend in the adjacent AVS ventricle. Data are presented as log2 fold difference compared to the right ventricle of the CAD patients.
*P < 0.05 vs. RVCAD and
#P < 0.05 vs. LVCAD.
Fold diff. = Fold difference.
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in left ventricle is cardioprotective against ischemia/reoxy-
genation [29]. These findings suggest more stress associ-
ated with coronary disease in the left compared to right
ventricle in view of its higher force generated and there-
fore more need for energy substrates.
Nucleobindin 1 is a calcium-binding protein and there-
fore can be involved in calcium storage and signaling
[30-33]. This may be required for the relatively higher
stress in the left ventricle. The higher MAP7 domain-
containing protein 1 in left ventricle compared to right is
again likely to be associated with different structure (mi-
crotubules) in the thicker left ventricle. Glycogen synthase
increased in the left ventricle compared to the rightventricle which implies the left side is storing more glyco-
gen compared to the right or that there is more use of
glycogen due to relatively more work by the left ventricle.
Differential protein expression between the hypertrophic
left ventricle of AVS and left ventricle of CAD patients are
hypertrophy and disease signaling related proteins
In an earlier study we compared left ventricles of hearts
with CAD with left ventricle from hearts with AVS and
found that hypertrophic ventricle had significantly higher
concentrations of ATP, but lower concentrations of lactate,
branched-chain amino acids and alanine [34]. These differ-
ences have important implications for energy metabolism
and protein turnover in the two pathologies. Comparison
Table 4 Inter-disease trends: other proteins
Log2 fold diff. vs. RVCAD
Protein [Swiss-Prot accession number] LVCAD RVAVS LVAVS
Adenylyl cyclase-associated protein 2 [P40123] 0.01 0.49*# 0.50
Sarcolemmal membrane-associated protein [Q14BN4] 0.11 0.48*# 0.37
Dynamin-like 120 kDa protein, mitochondrial [O60313] 0.15 0.43*# 0.31
Calnexin [P27824] 0.10 0.39*# 0.20
Popeye domain-containing protein 2 [Q9HBU9] 0.03 0.38*# 0.22
CDGSH iron-sulfur domain-containing protein 1 [Q9NZ45] 0.11 0.36*# 0.28
Ubiquitin-conjugating enzyme E2 L3 [P68036] −0.04 0.16*# 0.28
Protein Smaug homolog 1 [Q9UPU9] 0.18 0.63* 0.51
Myelin basic protein [P02686] 0.29 0.61* 0.61
Ras-related protein R-Ras2 [P62070] 0.25 0.61* 0.66
BRISC and BRCA1-A complex member 1 [Q9NWV8] 0.23* 0.45* 0.55
28S ribosomal protein S36, mitochondrial [P82909] 0.17 0.34* 0.31
Protein QIL1 [Q5XKP0] 0.14 0.34* 0.26
LIM domain-binding protein 3 [O75112] 0.19 0.33* 0.23
ES1 protein homolog, mitochondrial [P30042] 0.16* 0.29* 0.27
Transitional endoplasmic reticulum ATPase [P55072] 0.06 0.22* 0.12
Anion exchange protein 3 [P48751] −0.09 −0.40* −0.26
Complement C3 [P01024] 0.08 −0.80* −0.67
Cysteine and glycine-rich protein 3 [P50461] 0.01 0.57# 0.37
Eukaryotic translation initiation factor 5B [O60841] −0.10 0.30# 0.26
Calpastatin [P20810] 0.34 0.76 0.69*
Protein PBDC1 [Q9BVG4] 0.13 0.26 0.34*
Proline-rich basic protein 1 [E7EW31] −0.02 −0.26 −0.41*
Other proteins significantly altered in one of the AVS ventricles compared to either the left or right ventricle of CAD group and had a similar trend in the adjacent
AVS ventricle. Data are presented as log2 fold difference compared to the right ventricle of the CAD patients.
*P < 0.05 vs. RVCAD and
#P < 0.05 vs. LVCAD.
Fold diff. = Fold difference.
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have identified nine differentially and significantly expressed
proteins. Proteins were either higher (n = 3) or lower (n = 6)
in the hypertrophic left ventricle compared to left ventricle
of patients with CAD. The three proteins that were higher
in AVS patients were; glycogen synthase, sodium channel
protein type 5 subunit alpha (Nav1.5) and the mitochon-
drial 2-oxoisovalerate dehydrogenase subunit alpha. The
relatively higher glycogen synthase in hypertrophy is in
concert with the expanding myocytes having a greater
glycogen content [35]. The relatively higher expression of
Nav1.5 has also been seen at the gene expression level in a
model of hypertrophy [36]. In contrast there are reports
showing that oxidative stress triggers a decrease in the ex-
pression of Nav1.5 [37] which is likely to be seen in the
left ventricle with atherosclerosis (an inflammatory dis-
ease associated with oxidative stress). Therefore it is not
clear whether the difference in Nav1.5 expression is due
to an increase in hypertrophy, a decrease in CAD pa-
tients or a combination of both. The higher expressionof mitochondrial 2-oxoisovalerate dehydrogenase sub-
unit alpha may be related to energy production within
the mitochondria but 2-oxoisovalerate has been shown
to produce little ATP [38].
There were six proteins that had lower expression in
hypertrophic compared to CAD left ventricle: myome-
sin 1 and 2, glutathione S-transferase P, proactivator
polypeptide, heterogeneous nuclear ribonucleoproteins
C1/C2 and apoptotic chromatin condensation inducer
in the nucleus. The myomesins are elastic proteins
mostly located in the center of the M-band [39] and
may have implications for hypertrophic cardiomyopathy
[40]. Glutathione S-transferase P is involved in the re-
generation of reduced thiols [41] and therefore the rela-
tively lower levels may indicate disruption to oxidative
state in the hypertrophic myocardium. Interestingly the
expression of glutathione-S-transferase α3 tends to in-
crease in atherosclerotic coronary arteries compared to
control [42]. Proactivator polypeptide also called prosapo-
sin is cleaved into 4 different saposins which stimulate the
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mainly the precursor form [43]. Heterogeneous nuclear
ribonucleoproteins are modular proteins characterized
by extensive and divergent functions in nucleic acid me-
tabolism. Multiple roles in transcriptional and posttran-
scriptional regulation enable them to be effective gene
expression regulators [44]. Finally, the apoptotic chroma-
tin condensation inducer in the nucleus is a caspase-3-
activated protein required for apoptotic chromatin
condensation [45] and its lower expression in hypertrophy
suggests lower apoptotic activity in the hypertrophic heart
or increased apoptosis in the CAD patients.
73 proteins in right ventricles of AVS are differentially
expressed (89% higher) compared to CAD right ventricle
There was a large number of proteins differentially
expressed (significant and greater than 1.2 fold differ-
ence) between the right ventricle of AVS and the right
ventricle of CAD patients (Additional file 1: Table S2-
S4). This is an interesting and surprising finding as the
right ventricle is often assumed to be normal in a patient
with disease in the left ventricle. The proteins with al-
tered expression included metabolism, cell signaling and
structural. Metabolism-related proteins (n = 22) with
high-fold difference had higher expression in the AVS
right ventricle compared to CAD right ventricle that
were mostly mitochondrial. These changes are indicative
of higher metabolic activity in the right ventricle of AVS
which is surprising as it is widely accepted that only the
left ventricle undergoes significant remodeling. What is
more surprising is the finding that several structural pro-
teins were also differential higher in the right ventricle
of AVS compared to CAD as the AVS right ventricle
does not become hypertrophic. Finally, several of the sig-
naling proteins that were differentially expressed in AVS
right ventricle are associated with survival and death in-
dicating a relatively more stressed ventricle compared to
CAD right ventricle.
Comparison between two diseases: proteins differentially
expressed between ventricles of the two diseases often
show a similar trend in the adjacent ventricles
Many of the proteins which demonstrated a difference
in one ventricle of one pathology also showed a similar
trend in the adjacent ventricle of the same pathology.
There were four proteins that had significantly either
higher (n = 3) or lower (n = 1) expression in both left
and right ventricles of patients with AVS compared to
both ventricles of patients with CAD (Table 1). These
have already been discussed when comparing left ventri-
cles from both pathologies; glycogen synthase, mito-
chondrial 2-oxoisovalerate dehydrogenase subunit alpha,
sodium channel protein type 5 subunit alpha and apop-
totic chromatin condensation inducer in the nucleus.Additionally there were 26 proteins that showed
higher expression in both ventricles of AVS patients
compared to one of the ventricles in CAD patients
(Table 1). Of particular interest are: hexokinase 1, amine
oxidase [flavin-containing] A (also known as monoamine
oxidase type A (MAO-A)) and the anti-oxidant enzyme
peroxiredoxin-1. Hypertrophic hearts have an increased
level of glycolysis [46] which would explain the higher
levels of hexokinase. Up regulation of MAO-A in the
heart causes oxidative mitochondrial damage and chronic
ventricular dysfunction which might then promote the
upregulation of the anti-oxidant, peroxiredoxin-1 [47]. In
total, there were 102 proteins which demonstrated this
trend to change (84% higher in AVS) in both ventricles of
one disease compared to the other disease.
Protein expression and post-translational modifications
Post-translational modifications (PTMs) of proteins are the
key step responsible for regulation of protein activity and
function [48,49]. Therefore although our proteomes ana-
lysis provide an insight into differences between protein ex-
pression due to disease and anatomical location, knowledge
of PTMs is essential for making firm conclusions as to
whether these differences are relevant functionally. PTMs
of proteins include phosphorylation, glycosylation, methyla-
tion, and acetylation. Recent technological advances are
providing the tools for characterisation of PTMs including
mass spectrometry to determine the extent of protein phos-
phorylation (e.g. [50]). Therefore future studies of PTMs
are essential for better understanding of the importance of
proteome changes in cardiac disease.
Conclusions
This work demonstrates for the first time that left and
right ventricles of patients with either AVS or CAD have a
different proteome and that the difference is dependent
on the type of disease. Inter-disease differential expression
was more prominent for right ventricles compared to
the left ventricles. The finding that a protein change in
one ventricle was often associated with a similar trend
in the adjacent ventricle for a large number of proteins




Non-diabetic adult male patients (n = 8) with no prior
cardiac surgery were included in the study. Patients were
undergoing surgery for either aortic valve replacement
(n = 4) with no significant co-existing coronary artery
disease or coronary artery bypass grafting (n = 4). None
of the patients had current congestive heart failure and
they all had good left ventricular function. The New
York Heart Association (NYHA) classifications for AVS
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cations for CAD patients were I (n = 2) and II (n = 2).
One AVS patient had preoperative atrial fibrillation.
The investigation conforms to the principles outlined in
the Declaration of Helsinki. Local hospital ethical ap-
proval (ISRCTN84968882) as well as patient consent
was obtained.
Collection of ventricular biopsy
Immediately following the institution of cardiopulmo-
nary bypass, myocardial tissue biopsy specimens were
collected from the apex of the right and the left ventri-
cles using a 14 Ga. TW’11.4 cm cannula Trucut needle
(Baxter Healthcare Corporation, USA). Each specimen
was immediately snap frozen (less than 5 s) in liquid ni-
trogen and stored at −80°C until processing for protein
extraction and quantification.
Protein extraction and quantification
Proteins were extracted from ventricular samples using
mirVanaTM PARISTM RNA and protein purification kit
(Life Technologies, UK). Following extraction, samples
were incubated on ice for 30 min and then centrifuged
at 10,000 × g for 10 min. The supernatant was collected
and stored at −80°C. Protein content was determined
using the Bradford assay and samples were diluted to
2 mg · ml−1. A pooled sample was prepared by mixing an
equal volume of each sample and was used as an in-
ternal standard for normalization of each proteomics
analysis.
Proteomics
Analysis of proteins in ventricular tissues was performed
by the University of Bristol Proteomics Facility using tan-
dem mass tags (TMTs) (Thermo Fisher Scientific, UK).
Tandem mass tag labeling
Aliquots of each sample (100 μg) were reduced with
10 mM TCEP (incubated at 55°C for 1), alkylated with
17 mM iodoacetamide (incubated at room temperature
for 30 min) and then digested with trypsin (2.5 μg trypsin
per 100 μg protein; 37°C, overnight) and the resulting pep-
tides labeled with TMT sixplex reagents, all according to
the manufacturer’s protocol (Thermo Fisher Scientific,
UK). Each sample was labeled with a different isobaric tag
(6 per experimental comparison) and the tagged samples
were then combined.
Nano-liquid chromatography mass spectrometry/mass
spectrometry
The combined sample was fractionated using a Dionex
Ultimate 3000 nano high-performance liquid chroma-
tography system in line with an LTQ-Orbitrap Velos
mass spectrometer (Thermo Scientific, UK). In brief,peptides in 1% (v/v) formic acid were injected onto an
Acclaim PepMap C18 nano-trap column (Dionex, USA).
After washing with 0.5% (v/v) acetonitrile 0.1% (v/v) for-
mic acid peptides were resolved on a 250 mm × 75 μm
Acclaim PepMap C18 reverse phase analytical column
(Dionex, USA) over a 150 min organic gradient, using 7
gradient segments (1-6% solvent B over 1 min, 6-15% B
over 58 min, 15-32% B over 58 min, 32-40% B over
3 min, 40-90% B over 1 min, held at 90% B for 6 min
and then reduced to 1% B over 1 min) with a flow rate
of 300 nL · min−1. Solvent A was 0.1% formic acid and
solvent B was aqueous 80% acetonitrile in 0.1% formic
acid. Peptides were ionized by nano-electrospray
ionization at 2.0 kV using a stainless steel emitter with
an internal diameter of 30 μm (Thermo Scientific, UK)
and a capillary temperature of 250°C. Tandem mass
spectra were acquired using an LTQ-Orbitrap Velos
mass spectrometer controlled by Xcalibur 2.1 software
(Thermo Scientific, UK) and operated in data-dependent
acquisition mode. The Orbitrap was set to analyze the
survey scans at 60,000 resolution (at m/z 400) in the
mass range m/z 300 to 1800 and the top ten multiply
charged ions in each duty cycle selected for MS/MS
fragmentation using higher-energy collisional dissoci-
ation with normalized collision energy of 45%, activation
time of 0.1 ms and at a resolution of 7500 within the
Orbitrap. Charge state filtering, where unassigned pre-
cursor ions were not selected for fragmentation, and dy-
namic exclusion (repeat count 1; repeat duration 30 s;
exclusion list size 500) were used.
The raw data files were processed and quantified using
Proteome Discoverer software v1.2 (Thermo Scientific, UK)
and searched against the reviewed Swiss-Prot human data-
base (20,243 entries) using the SEQUEST (Ver. 28 Rev. 13)
algorithm. Peptide precursor mass tolerance was set at
10 ppm, and MS/MS tolerance was set at 20mmu. Search
criteria included oxidation of methionine (+15.9949) as
a variable modification and carbamidomethylation of
cysteine (+57.0214) and the addition of the TMT sixplex
mass tag (+229.163 Da) to peptide N-termini and lysine
as fixed modifications. Searches were performed with
full tryptic digestion and a maximum of one missed
cleavage was allowed. The reverse database search op-
tion was enabled and all peptide data was filtered to sat-
isfy false discovery rate (FDR) of 5%. The Proteome
Discoverer software generates a reverse “decoy” data-
base from the same protein database and any peptides
passing the initial filtering parameters that were derived
from this decoy database are defined as false positive
identifications. The minimum cross-correlation factor
filter was readjusted for each individual charge state
separately to optimally meet the predetermined target
FDR of 5% based on the number of random false posi-
tive matches from the reverse decoy database. Thus
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tion was done using a peak integration window toler-
ance setting of 0.0075 Da with the integration method
set as the most confident centroid.Western blotting
Extracted proteins (10 μg) were separated using SDS-
polyacrylamide gel electrophoresis under reducing and
denaturing conditions and transferred to a 0.45 μm
polyvinylidene difluoride membrane. The membranes
were blocked with tris-buffered saline (TBS)-Tween
containing 10% (w/v) skimmed milk powder before in-
cubation overnight (4°C) with a primary antibody di-
luted in TBS-Tween containing 5% (w/v) BSA. Primary
antibodies used included catalase (1:2000, Abcam) and
GAPDH (1:10,000, Cell Signaling). Membranes were
then incubated with an anti-rabbit horseradish perox-
idase conjugated secondary antibody (1:10,000, GE Health-
care Life Sciences) and proteins were visualized using the
enhanced chemiluminescence system (Amersham). Pro-
tein bands were quantified by densitometry with ImageJ
1.46r software.Data analysis
For proteomics analysis protein ratios represent the
median of the measured peptide ratio(s) for each.
Using this quantitative proteomic approach, the data
analysis was set so that any missing reporter ions
(TMT tags) in each MS/MS spectra are replaced with a
minimum intensity value, such that a protein ratio
value is generated even if that protein is not detected
in one of the samples in a single run (sixplex) of prote-
omic analysis. In the current study the maximum fold
change was set to 100, meaning that any protein show-
ing a protein ratio of 100 was not detected in one of
the samples under comparison. No such proteins were
identified. Values for each identified protein were pre-
sented as a ratio to the internal standard and then nor-
malized to GAPDH measured using proteomics.
Volcano plots were created by plotting log2 (fold differ-
ence) on the horizontal axis and –log10 (P-value) on
the vertical axis [51]. A log2 fold difference of more
than 0.25 (±1.2 fold difference) was considered as
high-fold difference and was used as the main focus for
presenting and discussing the data. We opted for the
relatively low cutoff as the majority of the highly sig-
nificant changes could be accommodated at around 1.2
fold higher (or lower). Other proteomic studies have
also used similar cut-off values [52-54]. Other data are
presented as mean ± SEM. All statistical tests were
performed as two-tailed and a P-value less than 0.05
was assumed to be significantly different.Additional file
Additional file 1: Table S1-S4. Proteins differentially expressed
between the ventricles of AVS and CAD patients.
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